OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New York Focused on Company’s Cytotoxic Monoclonal Antibody OSE-703 targeting IL-7R to treat cancer.
The collaboration will support a research program using OSE-703 (Effi-3), a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7 (CD127), cytotoxic for human cells expressing CD127.
“We are excited to collaborate with Dr. Adusumilli and one of the world’s most renowned cancer hospitals. The combination of his pioneering expertise in immuno-oncology, especially within CAR T-cell immunotherapy, and the therapeutic potential of OSE-703, will afford us optimal conditions to establish this promising product candidate’s efficacy profile and identify an appropriate development approach“ said Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics.